Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 172.6 EUR -1.93%
Market Cap: 12.9B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius AG
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Other Current Liabilities
€526.8m
CAGR 3-Years
7%
CAGR 5-Years
26%
CAGR 10-Years
17%
Carl Zeiss Meditec AG
XETRA:AFX
Other Current Liabilities
€182.8m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
9%
Stratec SE
XETRA:SBS
Other Current Liabilities
€21.4m
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
9%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Other Current Liabilities
€84.7m
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
15%
Siemens Healthineers AG
XETRA:SHL
Other Current Liabilities
€6.7B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Other Current Liabilities
€606.4m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
5%
No Stocks Found

Sartorius AG
Glance View

Market Cap
11.9B EUR
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SRT Intrinsic Value
184.25 EUR
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Sartorius AG's Other Current Liabilities?
Other Current Liabilities
526.8m EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Other Current Liabilities amounts to 526.8m EUR.

What is Sartorius AG's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
17%

Over the last year, the Other Current Liabilities growth was 18%. The average annual Other Current Liabilities growth rates for Sartorius AG have been 7% over the past three years , 26% over the past five years , and 17% over the past ten years .

Back to Top